Health Care; Pharmaceutical; Diagnostic; Medical Device; Biopharmaceutical; Academic; Research; Consulting; Biotech; Consumer Products; Education; Science; Clinical Research; Laboratories
Abbott; Uroplasty; Avanir; Duke University and Health System; B.Braun; Haemonetics Corporation; Medicines Differentiation Analytics; Abbvie; PharMedium; Lupin; Poxel; AstraZeneca; Medunik Canada; Bayer Healthcare; MD Outlook; Acorda Therapeutics; Purdue Pharma; Biogen Idec; Reliance Institute of Life Sciences; Boehringer Ingelheim; Xenoport; cipla; Catalent Pharma Solutions; Covidien; Teva Pharmaceutical Industries Ltd; UCB Pharma; Sanofi; Novo Nordisk
Best Practices, LLC engaged 35 executives from 29 leading life sciences companies through a benchmarking survey. Segmentation analysis was key to examining trends and effective practices. Twelve participants from nine companies comprise the Mid-sized Company Segment. Most responses came from the United States and Canada (63%), followed by Asia (20%).